Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FOSTAMATIN · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Period 1 | EXPERIMENTAL | - |
| Period 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| FOSTAMATIN | DRUG | Oral tablets - single dose |
| Verapamil | DRUG | Oral tablets - administered 3 times daily over 4 days |
Inclusion Criteria: * Weight of at least 50 kg (110 lbs) and body mass index (BMI) between 18 and 35 kg/m2, inclusive. * Females must be of non-childbearing potential Exclusion Criteria: * History of clinically significant disease or disorder or presence of GI, hepatic or renal disease * Any clin...
Fostamatinib is a small molecule drug developed by AstraZeneca PLC (ticker AZN). It is a SYK inhibitor that has been studied in Phase 1 clinical development. Its therapeutic indications have not been disclosed.
Fostamatinib targets SYK, spleen tyrosine kinase. It acts as an inhibitor of this enzyme. SYK is a signaling molecule involved in immune cell activation, which is why SYK inhibitors are studied across a range of conditions.
Fostamatinib is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor associated with the clinical development of this SYK inhibitor small molecule.
Fostamatinib is in Phase 1 clinical development. It is an investigational small molecule and has not been approved by the FDA. The Phase 1 program includes one completed trial, and no trials are currently active.
Fostamatinib has been evaluated in one completed Phase 1 trial, NCT01197781, titled Evaluation of the Drug-drug Interaction Between FosD and Verapamil When Taken Together in Healthy Volunteers. That trial enrolled 15 healthy adult volunteers in the United States and used a controlled design.
Yes, FosD is another name used for fostamatinib. The completed Phase 1 drug-drug interaction trial, NCT01197781, refers to the drug as FosD in its title, evaluating the interaction between FosD and verapamil when taken together in healthy volunteers.